Browse result page of THPdb

The total number entries retrieved from this search are 15

ID	ThPPID	Name	Peptide Sequence	Length	Functional Classification	Disease	Brand	Company	Physical Appearance	Route of Administartion	Category	Target
ID1537	ThPPIDTh1116	NameCanakinumab	Peptide SequenceH-GAMMA-1 (VH(1-118) Full view	Length842	Functional ClassificationIIIb	DiseaseImmunological	BrandILARISÂÂÂ	CompanyNovartis Pharmaceuticals	Physical AppearanceWhite, preservative-free, lyophilized powder	Route of AdministartionSubcutaneous injection	CategoryAnti-Inflammatory Agents and Monoclonal antibodies	TargetInterleukin-1 beta
ID1548	ThPPIDTh1117	NameIpilimumab	Peptide SequenceHeavy chain: QVQLVES Full view	Length663	Functional ClassificationIIIc	DiseaseCancer	BrandYERVOY	CompanyBristol-Myers Squibb	Physical AppearanceSterile, preservative-free, clear to slightly opalescent, colorless to pale-yellow solution	Route of AdministartionN.A.	CategoryAntineoplastic Agents and Monoclonal antibodies	TargetCytotoxic T-lymphocyte protein 4
ID1560	ThPPIDTh1121	NamePertuzumab	Peptide Sequencelight chain DIQMTQSP Full view	Length664	Functional ClassificationIIIc	DiseaseCancer	BrandPerjeta	CompanyGenentech	Physical AppearanceSterile, clear to slightly opalescent, colorless to pale brown liquid	Route of AdministartionIntravenous infusion	CategoryMonoclonal antibodies	TargetReceptor tyrosine-protein kinase erbB-2
ID1570	ThPPIDTh1123	NameDenosumab	Peptide SequenceHeavy chain EVQLLESG Full view	Length664	Functional ClassificationIIIc	DiseaseOsteological	BrandXgeva	CompanyAmgen.	Physical AppearanceSterile, preservative-free, clear, colorless to pale yellow solution	Route of AdministartionN.A.	CategoryBone Density Conservation Agents and Monoclonal antibodies	TargetTumor necrosis factor ligand superfamily member 11
ID1571	ThPPIDTh1123	NameDenosumab	Peptide SequenceHeavy chain EVQLLESG Full view	Length664	Functional ClassificationIIIc	DiseaseOsteological	BrandProlia	CompanyAmgen.	Physical AppearanceSterile, preservative-free, clear, colorless to pale yellow solution	Route of AdministartionN.A.	CategoryBone Density Conservation Agents and Monoclonal antibodies	TargetTumor necrosis factor ligand superfamily member 11
ID1583	ThPPIDTh1125	NameGolimumab	Peptide SequenceN.A. Full view	Length0	Functional ClassificationIIb	DiseaseImmunological	BrandSimponi Injection	CompanyN.A.	Physical AppearanceClear to slightly opalescent, colorless to light yellow solution	Route of AdministartionSubcutaneous injection	CategoryAntipsoriatic Agents and Monoclonal antibodies and TNF inhibitor	TargetTumor necrosis factor
ID1584	ThPPIDTh1125	NameGolimumab	Peptide SequenceN.A. Full view	Length0	Functional ClassificationIIb	DiseaseImmunological	BrandSimponi Injection	CompanyN.A.	Physical AppearanceSterile concentrated solution of the golimumab antibody	Route of AdministartionIntravenous infusion	CategoryAntipsoriatic Agents and Monoclonal antibodies and TNF inhibitor	TargetTumor necrosis factor
ID1609	ThPPIDTh1132	NameBelimumab	Peptide SequenceN.A. Full view	Length0	Functional ClassificationIIa	DiseaseImmunological	BrandBenlysta	CompanyGlaxoSmithKline	Physical AppearanceSterile, white to off-white, preservative-free, lyophilized powder	Route of AdministartionIntravenous infusion	CategoryMonoclonal antibodies	TargetTumor necrosis factor ligand superfamily member 13B
ID1627	ThPPIDTh1138	NameRaxibacumab	Peptide SequenceN.A. Full view	Length0	Functional ClassificationIIa	DiseaseImmunological/Infectious	BrandRAXIBACUMAB	CompanyGSK	Physical AppearanceSterile, liquid formulation in single-dose vials	Route of AdministartionN.A.	CategoryAnti-Infective Agents and Monoclonal antibodies	TargetProtective antigen
ID1708	ThPPIDTh1170	NameBlinatumomab	Peptide SequenceDIQLTQSPASLAVSLGQRAT Full view	Length504	Functional ClassificationIIIc	DiseaseCancer/Genetic	BrandBlincyto	CompanyAMGEN	Physical AppearanceLyophilized Powder for intravenous administration	Route of AdministartionIntravenous	CategoryAntineoplastic Agents, Immunosuppressive Agents, Monoclonal antibodies, Antineoplastic and Immunomodulating Agents	TargetB-lymphocyte antigen CD19; T-cell surface glycoprotein CD3 delta chain
ID1828	ThPPIDTh1218	NameAnti-thymocyte Globulin (Equine)	Peptide SequenceNA Full view	Length0	Functional ClassificationIIIb	DiseaseImmunological Disorders	BrandATGAM	CompanyNA	Physical Appearance Solid	Route of Administartion Intravenous	CategoryAntibody	TargetNA
ID1829	ThPPIDTh1219	NameAnti-thymocyte Globulin (Rabbit)	Peptide SequenceNA Full view	Length0	Functional ClassificationIIIb	DiseaseImmunological Disorders	BrandATG-Fresenius	CompanyGenzyme Inc.	Physical AppearanceConcentrate for solution for infusion.	Route of Administartion Intravenous	CategoryAntibody	TargetT-cell surface glycoprotein CD1a, Major histocompatibility complex class I-related gene protein, Integrin alpha-L, T-lymphocyte activation antigen CD86, Low affinity immunoglobulin gamma Fc region receptor II-b, T-cell surface glycoprotein CD4, Integrin beta-1, Integrin alpha-V, Integrin beta-3
ID1837	ThPPIDTh1226	NameDinutuximab	Peptide SequenceNA Full view	Length0	Functional ClassificationIIIc	DiseaseCancer	Brandunituxin	CompanyNA	Physical Appearancesterile, preservative-free, clear/colorless to slightly opalescent solution	Route of AdministartionIntravenous	CategoryAntibody, Immunosuppresive agent, Antineoplastic agent	TargetGanglioside GD2 (small molecule)
ID1842	ThPPIDTh1230	NameHuman Varicella-Zoster Immune Globulin	Peptide SequenceNA Full view	Length0	Functional ClassificationIIIa	DiseaseInfectious Disease	BrandVARIZIG	CompanyNA	Physical Appearancelyophilized powder for solution	Route of AdministartionIntramuscular	CategoryAntibody	Targetvaricella zoster virus
ID1843	ThPPIDTh1231	NameIbritumomab tiuxetan	Peptide SequenceHeavy chain: QAYLQQS Full view	Length652	Functional ClassificationIIIc	DiseaseCancer	BrandZevalin	CompanySpectrum Pharmaceuticals B.V.	Physical AppearanceColourless Solution	Route of AdministartionIntravenous	CategoryAntibody, Immunosuppressive Agents	TargetB-lymphocyte antigen CD20, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c